Poor
Needs Revision
Patient Risk:
Moderate
Summary
Only a subset of claims can be checked against the provided QAMZOVA (meloxicam) label excerpts (boxed warning; CV thrombotic risk; GI bleeding/ulceration/perforation; CABG contraindication). Many other claims are not supported by the supplied excerpts and several are not label-consistent or unverifiable (e.g., acetaminophen/combination assertions, pregnancy/breastfeeding/age advice, specific dosing caps, and administration with food).
Category Scores
Accurate Statements
Meloxicam carries cardiovascular warnings.
Boxed Warning and 5.1 Cardiovascular Thrombotic Events: increased risk of serious cardiovascular thrombotic events including MI and stroke; risk may occur early and increase with duration.
Meloxicam is associated with ulcers or bleeding.
Boxed Warning and 5.2 Gastrointestinal Effects: increased risk of serious GI adverse events including bleeding, ulceration, and perforation.
The combination should be taken with food to protect the stomach.
null
Meloxicam can cause elevated blood pressure or kidney strain.
null
Meloxicam prescribing information does not list acetaminophen as a contraindication.
null
Unsupported Statements
Acetaminophen primarily acts centrally on pain and fever without major anti-inflammatory effects.
No acetaminophen pharmacology/mechanism statements are present in the provided QAMZOVA label excerpts.
For most adults, taking meloxicam and Tylenol together at recommended doses is generally safe.
No combination safety statement between QAMZOVA/meloxicam and acetaminophen is included in the provided excerpts.
Meloxicam prescribing information does not list acetaminophen as a contraindication.
The provided excerpts do not include a complete contraindications list beyond CABG; absence of acetaminophen cannot be concluded from the supplied text.
Studies show no significant pharmacokinetic interactions between meloxicam and acetaminophen.
No pharmacokinetic interaction evidence is included in the provided label excerpts (and no Drug Interactions section text was supplied).
Meloxicam is prescribed in combination with acetaminophen for short-term conditions such as arthritis or post-surgical pain.
The provided excerpts do not include approved indication(s) or combination therapy statements.
Acetaminophen does not cause ulcers or bleeding.
No acetaminophen-specific GI risk comparison is present in the provided QAMZOVA label excerpts.
Acetaminophen overdose can cause liver toxicity.
No acetaminophen overdose/liver toxicity statements are present in the provided QAMZOVA label excerpts.
Meloxicam can cause elevated blood pressure or kidney strain.
No label text for blood pressure or kidney effects is included in the provided excerpts.
The risk of side effects from meloxicam may be higher in older adults and in people with heart or kidney issues.
The provided excerpts mention increased absolute incidence in patients with CV risk factors and increased GI risk in elderly, but do not support this broader claim about overall side effects or kidney specifically.
People with liver disease, heavy alcohol use, or who take other liver-stressing drugs should skip or consult a doctor before using the combination.
No liver disease/heavy alcohol/liver-stressing drugs guidance is present in the provided excerpts for the combination.
People with a history of ulcers, bleeding disorders, or NSAID allergies should skip or consult a doctor before using the combination.
While 5.2 describes risk factors for GI bleeding (including prior peptic ulcer disease and GI bleeding) and other risk factors, the provided excerpts do not support the specific 'skip or consult' instruction nor do they include NSAID allergy/bleeding disorder contraindication language.
Pregnancy (especially third trimester) is a reason to avoid or consult a doctor before using the combination.
No pregnancy guidance is included in the provided label excerpts.
Breastfeeding is a reason to avoid or consult a doctor before using the combination.
No lactation/breastfeeding guidance is included in the provided label excerpts.
Use in people under 18 is a reason to avoid or consult a doctor before using the combination.
No pediatric age restriction guidance is included in the provided label excerpts.
People with heart failure, high blood pressure, or kidney problems should skip or consult a doctor before using the combination.
The provided excerpts do not include specific heart failure/high blood pressure/kidney guidance.
Max recommended acetaminophen is 3 g/day for most people.
No acetaminophen dosing limits are present in the provided QAMZOVA label excerpts.
Do not exceed meloxicam 15 mg/day.
No dosing instructions for QAMZOVA (or meloxicam oral/max daily dose) are included in the provided excerpts.
The combination should be taken with food to protect the stomach.
No administration-with-food instruction is present in the provided excerpts.
Clinical trials and reviews (including a 2019 meta-analysis in Pain Medicine) confirm the combination provides better analgesia than either meloxicam or acetaminophen alone for osteoarthritis.
The provided excerpts do not include efficacy/clinical trial evidence or approved indication(s) for osteoarthritis/combination analgesia.
The 2019 meta-analysis found no increased adverse events at standard doses for the meloxicam-acetaminophen combination.
No such study/meta-analysis findings are included in the provided label excerpts.
Real-world data from over 1 million users shows low interaction rates for the meloxicam-acetaminophen combination.
No real-world interaction data is included in the provided label excerpts.
Contradictions
Low
AI Statement
Meloxicam prescribing information does not list acetaminophen as a contraindication.
Label Reference
Label excerpts provided only show CABG contraindication in section 4; no complete contraindications list for acetaminophen was supplied.
Important Omissions
Boxed warning and key specifics to support safe use decisions (e.g., that NSAIDs including meloxicam increase risk of serious CV thrombotic events and serious GI events including perforation; risk can occur without warning; and guidance to use lowest effective dose for shortest duration).
Importance:
High
CABG-specific contraindication statement: NSAIDs are contraindicated in CABG surgery setting.
Importance:
Moderate
QAMZOVA-specific dosing/administration details (e.g., IV administration schedule, bolus/infusion instructions, maximum dose, and duration).
Importance:
High
Any label-supported contraindications and warnings beyond those excerpts provided (e.g., interactions, specific patient populations, monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims about safety of meloxicam/acetaminophen combination, dosing limits, and avoidance in pregnancy/breastfeeding/pediatrics are unsupported by the supplied QAMZOVA label excerpts. However, several core boxed warning concepts (CV thrombotic events; GI bleeding/ulceration/perforation) are consistent with the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Many claims cannot be verified or are unsupported by the supplied QAMZOVA (meloxicam injection) label excerpts, especially those about acetaminophen combination safety/effects, population-specific avoidance, and dosing/administration instructions.
Suggested Improvement
Limit statements to the provided on-label excerpts: (1) CV thrombotic risk (boxed warning/5.1) and use lowest effective dose/shortest duration; (2) serious GI risk (boxed warning/5.2); and (3) CABG contraindication (section 4/5.1). Remove or re-verify all acetaminophen-combination, dosing-max, administration-with-food, and pregnancy/pediatric/lactation claims using the corresponding full label sections.